Objective:Copper death-induced tumor cell death and immune checkpoint blockade therapy are highly selective.Combining their advantages and understanding their characteristics in bladder cancer is very important for th...Objective:Copper death-induced tumor cell death and immune checkpoint blockade therapy are highly selective.Combining their advantages and understanding their characteristics in bladder cancer is very important for the development of new targeted therapy.The identification of bladder cancer by screening the characteristic genes of copper death-related immune checkpoints provide a theoretical basis for the selection of adjuvant treatment options and the application of new targets.Methods:The expression samples of normal bladder tissue and bladder cancer were obtained from TCGA and GEO databases,and 13 cop-per death genes and 79 immune checkpoint genes were extracted from previous studies.The mRNA expression of prognostic genes was verified by qPCR.The copper death-related immune checkpoint genes were screened by correlation analysis to construct a prognostic model,and the differences in the efficacy of immunotherapy and chemotherapy between the high-risk group and the low-risk group were evaluated.Results:A prognostic model consisting of BTNL9,CD160,TNFRSF14 and TNFRSF18 was constructed.Its reliable predictive ability was proved in both databases,and qPCR showed that the expression levels of the four genes were significantly different between the normal group and the cancer cell group.The effect of immunotherapy in the lowrisk group was better than that in the high-risk group.Patients in the high-risk group had better chemotherapy efficacy.Conclusion:The copper death-related immune checkpoint gene model can accurately predict the prognosis of patients.Drug and immune analysis provide a basis for clinical treatment,and the discovery of potential targets provides a new solution for clinical decision-making.展开更多
The ongoing research on pioneering drug candidates for the overactive bladder （OAB） aimed to overcome the limitations of currently licensed pharmacotherapies, such as antimuscarinics, β3-adrenergic agents, and botu...The ongoing research on pioneering drug candidates for the overactive bladder （OAB） aimed to overcome the limitations of currently licensed pharmacotherapies, such as antimuscarinics, β3-adrenergic agents, and botulinum neurotoxin, has been reviewed performing a systematic literature review and web search. The review covers the exploratory agents alternative to available medications for OAB and that may ultimately prove to be therapeutically useful in the future mana-gement of OAB patients based on preclinical and early clinical data. It emerges that many alternative pharmacological strategies have been discovered or are under investigation in disease-oriented studies. Several potential therapeutics are known for years but still fnd obstacles to pass the clinical stages of development, while other completely novel compounds, targeting new pharmacological targets, have been recently discovered and show potential to translate into clinical therapeutic agents for idiopathic and neurogenic OAB syndrome. The global scenario of investigational drugs for OAB gives promise for the development of innovative thera-peutics that may ultimately prove effective as first, combined or second-line treatments within a realistic timescale of ten years.展开更多
Objective:The aim of this study was to evaluate the effects and safety of brucea javanica oil,mitomycin and BCG for preventing postoperative relapse of superficial bladder cancer through perfusion.Methods:From July 20...Objective:The aim of this study was to evaluate the effects and safety of brucea javanica oil,mitomycin and BCG for preventing postoperative relapse of superficial bladder cancer through perfusion.Methods:From July 2000 to May 2006,178 patients with primary superficial bladder cancer(Ta-1,G1-2) were divided into three groups after operation in random:57 patients in group A received perfusion of 60 mL 10% brucea javanica oil,and 66 patients in group B received perfusion of 20 mg mitomycin while 55 patients in group C received perfusion of 120 mg BCG.Eighteen perfusions per patient were carried out regularly a week after operation.Patients were followed up for clinical,analytical and cystoscopic evaluations every 3 months for 2 years.The tumor relapse rates and side effects after treatment were evaluated.Results:The relapse rate was 14.04%(8/57),34.85%(23/66) and 18.18%(10/55) in group A,B and C respectively.The relapse rate in group A was obviously lower than that in group B(χ2 = 6.17,P < 0.05).Disease free interval in group A was significantly different from that in group B(F = 7.03,P < 0.05).Side effect in group A(12.28%) was observably lower than that in group B(43.94%) and group C(83.64%)(χ2AB = 15.72,P < 0.01;χ2AC = 55.34,P < 0.01).Conclusion:Perfusion of 10% brucea javanica oil after operation is safer and more effective in preventing superficial bladder tumour relapse and worth for popularizing.展开更多
目的:系统评价M受体阻滞剂联合非药物方式治疗成年女性膀胱过度活动症(overactive bladder,OAB)的疗效及临床价值。方法:检索2015年1月前在Pub Med、Embase、Web of Science以及中国期刊全文数据库(CNKI)和中国生物医学文献数据库(CBWMD...目的:系统评价M受体阻滞剂联合非药物方式治疗成年女性膀胱过度活动症(overactive bladder,OAB)的疗效及临床价值。方法:检索2015年1月前在Pub Med、Embase、Web of Science以及中国期刊全文数据库(CNKI)和中国生物医学文献数据库(CBWMDisc)等已公开发表的关于M受体阻滞剂联合非药物与单用M受体阻滞剂相比治疗成年女性膀胱过度活动症(OAB)的随机对照试验,通过纳入标准和排除标准筛选文献。按照Jadad量表评价纳入研究的质量,采用Revman5.3进行meta分析。结果:共有7篇文献(共610例)符合纳入标准。其中M受体阻滞剂联合电刺激4篇,联合行为训练2篇,联合电刺激加行为训练1篇。Meta分析结果显示:(1)与对照组(单用M受体阻滞剂组)相比,M受体阻滞剂联合电刺激在降低日平均排尿次数(WMD=-0.60,95%CI=-1.23~0.03,P=0.06)、尿失禁次数(SMD=-4.45,95%CI=-12.77~3.86,P=0.29)方面疗效无统计学差异;但在降低尿急次数(WMD=-1.09,95%CI=-2.15^-0.03,P=0.04),提高临床总有效率(RR=1.24,95%CI=1.06~1.44,P=0.007)方面,M受体阻滞剂联合电刺激疗效优于对照组。(2)M受体阻滞剂联合行为训练在降低日平均排尿次数方面疗效优于对照组(WMD=-0.67,95%CI=-1.14^-0.20,P=0.005)。结论:M受体阻滞剂联合非药物治疗方式较单用M受体阻滞剂能够更好地改善成年女性OAB患者的部分排尿症状,提高临床总有效率。展开更多
基金Key Research Project of Sichuan Provincial Department of Science and Technology(No.23ZDYF1246)。
文摘Objective:Copper death-induced tumor cell death and immune checkpoint blockade therapy are highly selective.Combining their advantages and understanding their characteristics in bladder cancer is very important for the development of new targeted therapy.The identification of bladder cancer by screening the characteristic genes of copper death-related immune checkpoints provide a theoretical basis for the selection of adjuvant treatment options and the application of new targets.Methods:The expression samples of normal bladder tissue and bladder cancer were obtained from TCGA and GEO databases,and 13 cop-per death genes and 79 immune checkpoint genes were extracted from previous studies.The mRNA expression of prognostic genes was verified by qPCR.The copper death-related immune checkpoint genes were screened by correlation analysis to construct a prognostic model,and the differences in the efficacy of immunotherapy and chemotherapy between the high-risk group and the low-risk group were evaluated.Results:A prognostic model consisting of BTNL9,CD160,TNFRSF14 and TNFRSF18 was constructed.Its reliable predictive ability was proved in both databases,and qPCR showed that the expression levels of the four genes were significantly different between the normal group and the cancer cell group.The effect of immunotherapy in the lowrisk group was better than that in the high-risk group.Patients in the high-risk group had better chemotherapy efficacy.Conclusion:The copper death-related immune checkpoint gene model can accurately predict the prognosis of patients.Drug and immune analysis provide a basis for clinical treatment,and the discovery of potential targets provides a new solution for clinical decision-making.
文摘The ongoing research on pioneering drug candidates for the overactive bladder （OAB） aimed to overcome the limitations of currently licensed pharmacotherapies, such as antimuscarinics, β3-adrenergic agents, and botulinum neurotoxin, has been reviewed performing a systematic literature review and web search. The review covers the exploratory agents alternative to available medications for OAB and that may ultimately prove to be therapeutically useful in the future mana-gement of OAB patients based on preclinical and early clinical data. It emerges that many alternative pharmacological strategies have been discovered or are under investigation in disease-oriented studies. Several potential therapeutics are known for years but still fnd obstacles to pass the clinical stages of development, while other completely novel compounds, targeting new pharmacological targets, have been recently discovered and show potential to translate into clinical therapeutic agents for idiopathic and neurogenic OAB syndrome. The global scenario of investigational drugs for OAB gives promise for the development of innovative thera-peutics that may ultimately prove effective as first, combined or second-line treatments within a realistic timescale of ten years.
文摘Objective:The aim of this study was to evaluate the effects and safety of brucea javanica oil,mitomycin and BCG for preventing postoperative relapse of superficial bladder cancer through perfusion.Methods:From July 2000 to May 2006,178 patients with primary superficial bladder cancer(Ta-1,G1-2) were divided into three groups after operation in random:57 patients in group A received perfusion of 60 mL 10% brucea javanica oil,and 66 patients in group B received perfusion of 20 mg mitomycin while 55 patients in group C received perfusion of 120 mg BCG.Eighteen perfusions per patient were carried out regularly a week after operation.Patients were followed up for clinical,analytical and cystoscopic evaluations every 3 months for 2 years.The tumor relapse rates and side effects after treatment were evaluated.Results:The relapse rate was 14.04%(8/57),34.85%(23/66) and 18.18%(10/55) in group A,B and C respectively.The relapse rate in group A was obviously lower than that in group B(χ2 = 6.17,P < 0.05).Disease free interval in group A was significantly different from that in group B(F = 7.03,P < 0.05).Side effect in group A(12.28%) was observably lower than that in group B(43.94%) and group C(83.64%)(χ2AB = 15.72,P < 0.01;χ2AC = 55.34,P < 0.01).Conclusion:Perfusion of 10% brucea javanica oil after operation is safer and more effective in preventing superficial bladder tumour relapse and worth for popularizing.
文摘目的:系统评价M受体阻滞剂联合非药物方式治疗成年女性膀胱过度活动症(overactive bladder,OAB)的疗效及临床价值。方法:检索2015年1月前在Pub Med、Embase、Web of Science以及中国期刊全文数据库(CNKI)和中国生物医学文献数据库(CBWMDisc)等已公开发表的关于M受体阻滞剂联合非药物与单用M受体阻滞剂相比治疗成年女性膀胱过度活动症(OAB)的随机对照试验,通过纳入标准和排除标准筛选文献。按照Jadad量表评价纳入研究的质量,采用Revman5.3进行meta分析。结果:共有7篇文献(共610例)符合纳入标准。其中M受体阻滞剂联合电刺激4篇,联合行为训练2篇,联合电刺激加行为训练1篇。Meta分析结果显示:(1)与对照组(单用M受体阻滞剂组)相比,M受体阻滞剂联合电刺激在降低日平均排尿次数(WMD=-0.60,95%CI=-1.23~0.03,P=0.06)、尿失禁次数(SMD=-4.45,95%CI=-12.77~3.86,P=0.29)方面疗效无统计学差异;但在降低尿急次数(WMD=-1.09,95%CI=-2.15^-0.03,P=0.04),提高临床总有效率(RR=1.24,95%CI=1.06~1.44,P=0.007)方面,M受体阻滞剂联合电刺激疗效优于对照组。(2)M受体阻滞剂联合行为训练在降低日平均排尿次数方面疗效优于对照组(WMD=-0.67,95%CI=-1.14^-0.20,P=0.005)。结论:M受体阻滞剂联合非药物治疗方式较单用M受体阻滞剂能够更好地改善成年女性OAB患者的部分排尿症状,提高临床总有效率。
